Noblett Karen 4
4 · Axonics, Inc. · Filed Sep 20, 2022
Insider Transaction Report
Form 4
Axonics, Inc.AXNX
Noblett Karen
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2022-09-12$14.19/sh+18,519$262,785→ 50,118 total - Exercise/Conversion
Common Stock
2022-09-12$25.82/sh+13,964$360,550→ 64,082 total - Sale
Common Stock
2022-09-12$78.16/sh−32,483$2,538,800→ 31,599 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-09-12−18,519→ 2,963 totalExercise: $14.19Exp: 2029-01-30→ Common Stock (18,519 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2022-09-12−13,964→ 6,348 totalExercise: $25.82Exp: 2029-12-12→ Common Stock (13,964 underlying)
Footnotes (3)
- [F1]This transaction was executed in multiple trades at prices ranging from $78.00 to $78.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date.
- [F3]The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date.